journal
MENU ▼
Read by QxMD icon Read
search

Journal of Clinical Lipidology

journal
https://www.readbyqxmd.com/read/29339066/apolipoprotein-a-i-a-favorable-prognostic-marker-in-infective-endocarditis
#1
Xue-Biao Wei, Xiao-Jin Chen, Yuan-Ling Li, Jie-Leng Huang, Xiao-Lan Chen, Dan-Qing Yu, Ning Tan, Yuan-Hui Liu, Ji-Yan Chen, Peng-Cheng He
BACKGROUND: Decreased apolipoprotein A-I (apoA-I) and high-density lipoprotein cholesterol (HDL-C) are common in inflammation and sepsis. No study with a large sample size has been performed to investigate the prognostic value of apoA-I or HDL-C in infective endocarditis (IE). OBJECTIVE: The present study aimed to explore the prognostic value of apoA-I and HDL-C for adverse outcomes in IE patients. METHODS: Patients with a definite diagnosis of IE between January 2009 and July 2015 were enrolled and divided into 3 groups according to their apoA-I tertiles at admission...
December 21, 2017: Journal of Clinical Lipidology
https://www.readbyqxmd.com/read/29310989/visit-to-visit-variability-of-lipid-measurements-as-predictors-of-cardiovascular-events
#2
David D Waters, Sripal Bangalore, Rana Fayyad, David A DeMicco, Rachel Laskey, Shari Melamed, Philip J Barter
BACKGROUND: Higher visit-to-visit variability in risk factors such as blood pressure and low-density lipoprotein (LDL)-cholesterol are associated with an increase in cardiovascular (CV) events. OBJECTIVE: The purpose of this study was to determine whether variability in high-density lipoprotein cholesterol (HDL-C) and triglyceride levels predicted coronary and CV events in a clinical trial population with known coronary disease. METHODS: We assessed intraindividual variability in fasting high-density lipoprotein (HDL)-cholesterol, triglyceride, and LDL-cholesterol measurements among 9572 patients in the Treating to New Targets trial and correlated the results with coronary events over a median follow-up of 4...
December 20, 2017: Journal of Clinical Lipidology
https://www.readbyqxmd.com/read/29310992/interleukin-1-genotypes-modulate-the-long-term-effect-of-lipoprotein-a-on-cardiovascular-events-the-ioannina-study
#3
Katerina K Naka, Aris Bechlioullis, Aikaterini Marini, Dimitrios Sionis, Konstantinos Vakalis, Georgios Triantis, Leon Wilkins, John Rogus, Kenneth S Kornman, Joseph L Witztum, Lynn Doucette-Stamm, Lampros K Michalis, Sotirios Tsimikas
BACKGROUND: Lipoprotein(a) [Lp(a)] is a genetic risk factor for cardiovascular disease (CVD), and proinflammatory interleukin-1 (IL-1) genotypes may influence Lp(a)-mediated CVD events. The genotype IL-1(+) is associated with higher rates of inflammation than IL-1(-) genotype. Targeting IL-1β was recently shown to decrease CVD events independent of low-density lipoprotein-cholesterol levels. OBJECTIVE: The objective of the study is to assess the modulatory effect of IL-1 genotypes on risk mediated by Lp(a) METHODS: We assessed whether IL-1 genotypes modulate the effect of Lp(a) on major adverse cardiovascular events (cardiovascular death, myocardial infarction, and stroke/transient ischemic attack) and angiographically determined coronary artery disease (CAD)...
December 19, 2017: Journal of Clinical Lipidology
https://www.readbyqxmd.com/read/29292049/assessment-of-arterial-stiffness-in-patients-with-familial-hypercholesterolemia
#4
Hayato Tada, Masa-Aki Kawashiri, Atsushi Nohara, Akihiro Inazu, Hiroshi Mabuchi, Masakazu Yamagishi
BACKGROUND: Recently, the concept of severe familial hypercholesterolemia (FH) has been proposed to identify individuals at an extremely high risk of developing coronary artery disease (CAD) among patients with FH. Although the adverse effects of arterial stiffness have been proven in the general population, insufficient data exist regarding its clinical impact in patients with FH. OBJECTIVES: This study aimed to assess the association between arterial stiffness and CAD in patients with FH...
December 14, 2017: Journal of Clinical Lipidology
https://www.readbyqxmd.com/read/29290540/abo-blood-group-is-a-cardiovascular-risk-factor-in-patients-with-familial-hypercholesterolemia
#5
Martine Paquette, Robert Dufour, Alexis Baass
BACKGROUND: The ABO blood group has been associated with cardiovascular disease (CVD) in observational studies. However, the effect of ABO blood group has never been studied in subjects affected by familial hypercholesterolemia (FH), a severe monogenic disease characterized by accelerated atherosclerotic plaque development. OBJECTIVE: Our aim is to investigate the effect of the ABO blood group on CVD risk in FH patients. METHODS: A total of 668 adult subjects with a heterozygous FH-causing mutation in the low density lipoprotein receptor (LDLR) gene were included in the present study...
December 14, 2017: Journal of Clinical Lipidology
https://www.readbyqxmd.com/read/29287917/safety-of-statin-treatment-in-children-with-familial-hypercholesterolemia-filling-the-gaps
#6
EDITORIAL
Viviane Z Rocha, Raul D Santos
No abstract text is available yet for this article.
December 7, 2017: Journal of Clinical Lipidology
https://www.readbyqxmd.com/read/29310991/dyslipidemia-and-lipid-lowering-treatment-in-a-hematopoietic-stem-cell-transplant-cohort-25%C3%A2-years-of-follow-up-data
#7
Melanie Premstaller, Melanie Perren, Kuebra Koçack, Christian Arranto, Geneviève Favre, Andreas Lohri, Sabine Gerull, Jakob R Passweg, Jörg P Halter, Anne B Leuppi-Taegtmeyer
BACKGROUND: Dyslipidemia is common after hematopoietic stem cell transplantation (HSCT). Few data regarding the time course of lipid profiles after HSCT, the effect of multiple transplantations, and efficacy and safety of lipid-lowering treatments are available. OBJECTIVE: The objective of the study was to determine the prevalence and treatment of dyslipidemia over a 25-year period in a large, single-center cohort. METHODS: One thousand one hundred ninety-six adult patients (≥16 years) who underwent HSCT during 1973 to 2013 and who survived ≥100 days were studied retrospectively...
December 6, 2017: Journal of Clinical Lipidology
https://www.readbyqxmd.com/read/29310990/treatment-goal-attainment-in-children-with-familial-hypercholesterolemia-a-cohort-study-of%C3%A2-302-children-in-norway
#8
Martin P Bogsrud, Gisle Langslet, Cecilie Wium, Dan Johansen, Arne Svilaas, Kirsten B Holven
BACKGROUND: Consensus statements recommend that statin treatment in children with heterozygous familial hypercholesterolemia (FH) should be considered from 8 to 10 years of age. Although these recommendations are well known, less is known about actual treatment and treatment goal attainment in children with FH. OBJECTIVE: The objective of the study was to investigate if children with FH were treated according to current recommendations. METHODS: Retrospective collection of data from medical records of 302 children below 18 years visiting the Lipid Clinic, Oslo University hospital, during 2014 to 2016...
December 6, 2017: Journal of Clinical Lipidology
https://www.readbyqxmd.com/read/29277495/clinical-pharmacist-understanding-of-the-2013-american-college-of-cardiology-american-heart-association-cholesterol-guideline
#9
John D Bucheit, Haleigh Helsing, Pramit Nadpara, Salim S Virani, Dave L Dixon
BACKGROUND: Clinical pharmacists are frequently involved in the management of dyslipidemia, yet clinical pharmacists' knowledge, awareness, and the level of agreement with the 2013 American College of Cardiology (ACC)/American Heart Association (AHA) cholesterol guideline are unknown. OBJECTIVE: The objective of the study was to examine clinical pharmacists' knowledge, awareness, and the level of agreement with the 2013 ACC/AHA cholesterol guideline. METHODS: We administered a validated questionnaire via an online survey that was electronically mailed to clinical pharmacists...
December 6, 2017: Journal of Clinical Lipidology
https://www.readbyqxmd.com/read/29208363/the-uk-paediatric-familial-hypercholesterolaemia-register-statin-related-safety-and-1-year-growth-data
#10
Steve E Humphries, Jackie Cooper, Peter Dale, Uma Ramaswami
BACKGROUND: For children with familial hypercholesterolemia (FH), UK guidelines recommend consideration of statin therapy by age 10 years and dietary and lifestyle advice to maintain an ideal body weight. OBJECTIVES: The objective of the study is to use the UK Paediatric Familial Hypercholesterolemia Register to determine: (1) the prevalence of plasma markers of liver toxicity and muscle damage in statin-treated FH children; (2) the prevalence of obesity in FH children compared to the UK general population; and (3) to compare growth rates in statin-treated and nontreated children...
November 22, 2017: Journal of Clinical Lipidology
https://www.readbyqxmd.com/read/29217412/glucagon-like-peptide-1-receptor-agonists-reduced-the-low-density-lipoprotein-cholesterol-in-japanese-patients-with-type-ii-diabetes-mellitus-treated-with-statins
#11
Yukiko Hasegawa, Mika Hori, Tomoko Nakagami, Mariko Harada-Shiba, Yasuko Uchigata
BACKGROUND: Patients with type II diabetes mellitus (T2DM) often have hypercholesterolemia, and their serum low-density lipoprotein cholesterol (LDL-C) levels are not always well-controlled even by statin treatment. The glucose-lowering glucagon-like peptide-1 receptor agonists (GLP-1RAs) are reported to change the lipid profiles in T2DM patients, but their effects have been unclear. OBJECTIVE: We examined whether GLP-1RAs affect serum cholesterol levels in T2DM patients with/without statin treatment...
November 21, 2017: Journal of Clinical Lipidology
https://www.readbyqxmd.com/read/29198934/novel-polymorphisms-associated-with-hyperalphalipoproteinemia-and-apparent-cardioprotection
#12
Connor P Oates, Darya Koenig, Jeffrey Rhyne, Nikolay Bogush, Jeffrey O'Connell, Braxton D Mitchell, Michael Miller
BACKGROUND: Hyperalphalipoproteinemia (HALP) is inversely correlated with coronary heart disease (CHD) although genetic variants associated with high serum levels of high-density lipoprotein cholesterol (HDL-C) have not been shown to be cardioprotective. OBJECTIVE: The objective of the study was to uncover novel genetic variants associated with HALP and possibly with reduced risk of CHD. METHODS: Exome sequencing data, HDL-C, and triglyceride levels were analyzed in 1645 subjects...
November 21, 2017: Journal of Clinical Lipidology
https://www.readbyqxmd.com/read/29229363/comparison-of-the-effects-of-flaxseed-oil-and-sunflower-seed-oil-consumption-on-serum-glucose-lipid-profile-blood-pressure-and-lipid-peroxidation-in-patients-with-metabolic-syndrome
#13
Atefeh Akrami, Farzad Nikaein, Siavash Babajafari, Shiva Faghih, Hassan Yarmohammadi
BACKGROUND: Metabolic syndrome (MetSyn) increases the risk of type II diabetes and morbidity and mortality due to cardiovascular diseases. Flaxseed oil (FO), as a functional food, is one of the major vegetal sources of essential omega-3 fatty acids. OBJECTIVE: This study aimed to compare the effects of consumption of FO and sunflower seed oil (SO) on lipid peroxidation and other symptoms of MetSyn. METHODS: This randomized controlled interventional trial was conducted on 60 volunteers aged 30 to 60 years who were diagnosed with MetSyn in Shiraz, Iran...
November 20, 2017: Journal of Clinical Lipidology
https://www.readbyqxmd.com/read/29174072/acute-myocardial-infarction-in-a-25-year-old-woman-with-sitosterolemia
#14
Ryuki Kawamura, Hitoshi Saiki, Hayato Tada, Akihiro Hata
We report the case of acute myocardial infarction in a 25-year-old woman with sitosterolemia. She was treated using statins, but her low-density lipoprotein cholesterol (LDL-C) levels did not decrease appreciably. Genetic analysis revealed mutations in the ABCG8 gene. Ezetimibe treatment was initiated, and her LDL-C levels decreased substantially. Sitosterolemia must be considered in the differential diagnosis of familial hypercholesterolemia in case of early onset cardiovascular disease patient with high LDL-C...
November 20, 2017: Journal of Clinical Lipidology
https://www.readbyqxmd.com/read/29217413/apolipoprotein-e-containing-high-density-lipoprotein-hdl-modifies-the-impact-of-cholesterol-overloaded-hdl-on-incident-coronary-heart-disease-risk-a-community-based-cohort-study
#15
Yue Qi, Jing Liu, Wei Wang, Miao Wang, Fan Zhao, Jiayi Sun, Jun Liu, Dong Zhao
BACKGROUND: Experimental studies have shown that cholesterol-overloaded high-density lipoprotein (HDL) can promote the formation of apolipoprotein E (APOE)-containing HDL, a process correcting the atherogenic function of cholesterol-overloaded HDL. OBJECTIVE: The objective of the study was to explore whether APOE-containing HDL can attenuate the defective impact of cholesterol-overloaded HDL on the development of coronary heart disease (CHD) in humans. METHODS: We measured APOE-HDL cholesterol (APOE-HDLC), HDL cholesterol (HDLC), and HDL particle number in 1112 participants aged 45 to 74 years at baseline in a community-based cohort study...
November 14, 2017: Journal of Clinical Lipidology
https://www.readbyqxmd.com/read/29198898/levels-of-prebeta-1-high-density-lipoprotein-are-elevated-in-3-phenotypes-of-dyslipidemia
#16
Eveline Oestreicher Stock, Christine T Ferrara, Patricia M O'Connor, Josefina M Naya-Vigne, Philip H Frost, Mary J Malloy, John P Kane, Clive R Pullinger
BACKGROUND: Prebeta-1 high-density lipoprotein (HDL) is a small subspecies of HDL that functions as the HDL quantum particle and is the principal acceptor of cholesterol effluxed from macrophages through the ATP-binding cassette transporter, ABCA1. High levels of prebeta-1 HDL are associated with increased risk of structural coronary artery disease and myocardial infarction. OBJECTIVE: We aimed to compare prebeta-1 HDL levels in normal subjects and in 3 phenotypes of dyslipidemia...
November 14, 2017: Journal of Clinical Lipidology
https://www.readbyqxmd.com/read/29246729/a-comparison-of-the-effects-of-low-and-high-dose-atorvastatin-on-lipoprotein-metabolism-and-inflammatory-cytokines-in-type-2-diabetes-results-from-the-protection-against-nephropathy-in-diabetes-with-atorvastatin-panda-randomized-trial
#17
Handrean Soran, Yifen Liu, Safwaan Adam, Tarza Siahmansur, Jan H Ho, Jonathan D Schofield, See Kwok, Matthew Gittins, Michael France, Naveed Younis, J Martin Gibson, Paul N Durrington, Martin K Rutter
BACKGROUND: Statin therapy is recommended in type 2 diabetes (T2DM) although views on treatment intensity and therapeutic targets remain divided. OBJECTIVES: Our objectives were to compare the effects of high-intensity and moderate-intensity atorvastatin treatment on lipoprotein metabolism and inflammatory markers and how frequently treatment goals are met in high-risk T2DM patients. METHODS: Patients with T2DM and albuminuria (urinary albumin:creatinine ratio >5 mg/mmol, total cholesterol <7 mmol/L, proteinuria <2 g/d, creatinine <200 μmol/L) were randomized to receive atorvastatin 10 mg (n = 59) or 80 mg (n = 60) daily...
November 13, 2017: Journal of Clinical Lipidology
https://www.readbyqxmd.com/read/29195809/reduced-psychological-distress-in-familial-chylomicronemia-syndrome-after-patient-support-group-intervention
#18
Leah M Wilson, Russell R Cross, P Barton Duell
Familial chylomicronemia syndrome (FCS) is a rare genetic disorder that is associated with severe hypertriglyceridemia and complications that often include recurrent pancreatitis beginning in childhood. Patients with FCS frequently struggle to maintain normality in their lives as a consequence of the necessity to severely restrict their intake of dietary fat coupled with the constant threat of recurrent pancreatitis. Patients typically face a high level of psychological stress and anxiety in association with reduced measures of quality of life...
November 13, 2017: Journal of Clinical Lipidology
https://www.readbyqxmd.com/read/29246730/a-case-of-sitosterolemia-misdiagnosed-as-familial-hypercholesterolemia-a-4-year-follow-up
#19
Wei Wang, Long Jiang, Pan-Pan Chen, Yue Wu, Peng-Yu Su, Lu-Ya Wang
Familial hypercholesterolemia (FH) is a common inherited disease that exhibits significantly increased levels of low-density lipoprotein cholesterol (LDL-C), skin or tendon xanthomas, corneal arcus and premature coronary heart disease (CHD). The prevalence of heterozygous FH is nearly 1/300 worldwide, and the prevalence of homozygous FH (HoFH) is 1/160,000 - 1/300,000. The Dutch Lipid Clinic Network diagnostic (DLCN) criteria is the most commonly recommended criteria for diagnosing FH patients. However, another disease with a similar clinical phenotype to FH must be differentiated from FH...
November 11, 2017: Journal of Clinical Lipidology
https://www.readbyqxmd.com/read/29150341/increased-prevalence-of-clinical-and-subclinical-atherosclerosis-in-patients-with-damaging-mutations-in-abca1-or-apoa1
#20
Omar Abdel-Razek, Singh N Sadananda, Xuan Li, Lubomira Cermakova, Jiri Frohlich, Liam R Brunham
BACKGROUND: A low level of high-density lipoprotein cholesterol (HDL-C) is a common clinical scenario and poses challenges for management. Many patients with low HDL-C harbor a damaging mutation in ABCA1 or APOA1, but the clinical implications of genetic testing for these mutations are unclear. OBJECTIVE: The purpose of this study was to investigate the prevalence of clinical or subclinical atherosclerosis among patients with low HDL-C due to a mutation in ABCA1 or APOA1, compared with patients with low HDL-C without such a mutation...
November 10, 2017: Journal of Clinical Lipidology
journal
journal
41578
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"